Christine M Albert1,2, Nancy R Cook2,3, Julie Pester2, M Vinayaga Moorthy2, Claire Ridge2, Jacqueline S Danik4, Baris Gencer2, Hasan K Siddiqi2,5, Chee Ng4, Heike Gibson2, Samia Mora2,5, Julie E Buring2,3, JoAnn E Manson2,3. 1. Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California. 2. Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 3. Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts. 4. Division of Cardiovascular Medicine, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. 5. Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Abstract
Importance: Atrial fibrillation (AF) is the most common heart rhythm disturbance, continues to increase in incidence, and results in significant morbidity and mortality. The marine omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and vitamin D have been reported to have both benefits and risks with respect to incident AF, but large-scale, long-term randomized trial data are lacking. Objective: To test the effects of long-term administration of marine omega-3 fatty acids and vitamin D on incident AF. Design, Setting, and Participants: An ancillary study of a 2 × 2 factorial randomized clinical trial involving 25 119 women and men aged 50 years or older without prior cardiovascular disease, cancer, or AF. Participants were recruited directly by mail between November 2011 and March 2014 from all 50 US states and were followed up until December 31, 2017. Interventions: Participants were randomized to receive EPA-DHA (460 mg/d of EPA and 380 mg/d of DHA) and vitamin D3 (2000 IU/d) (n = 6272 analyzed); EPA-DHA and placebo (n = 6270 analyzed); vitamin D3 and placebo (n = 6281 analyzed); or 2 placebos (n = 6296 analyzed). Main Outcomes and Measures: The primary outcome was incident AF confirmed by medical record review. Results: Among the 25 119 participants who were randomized and included in the analysis (mean age, 66.7 years; 50.8% women), 24 127 (96.1%) completed the trial. Over a median 5.3 years of treatment and follow-up, the primary end point of incident AF occurred in 900 participants (3.6% of study population). For the EPA-DHA vs placebo comparison, incident AF events occurred in 469 (3.7%) vs 431 (3.4%) participants, respectively (hazard ratio, 1.09; 95% CI, 0.96-1.24; P = .19). For the vitamin D3 vs placebo comparison, incident AF events occurred in 469 (3.7%) vs 431 (3.4%) participants, respectively (hazard ratio, 1.09; 95% CI, 0.96-1.25; P = .19). There was no evidence for interaction between the 2 study agents (P = .39). Conclusions and Relevance: Among adults aged 50 years or older, treatment with EPA-DHA or vitamin D3, compared with placebo, resulted in no significant difference in the risk of incident AF over a median follow-up of more than 5 years. The findings do not support the use of either agent for the primary prevention of incident AF. Trial Registration: ClinicalTrials.gov Identifiers: NCT02178410; NCT01169259.
Importance: Atrial fibrillation (AF) is the most common heart rhythm disturbance, continues to increase in incidence, and results in significant morbidity and mortality. The marine omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and vitamin D have been reported to have both benefits and risks with respect to incident AF, but large-scale, long-term randomized trial data are lacking. Objective: To test the effects of long-term administration of marine omega-3 fatty acids and vitamin D on incident AF. Design, Setting, and Participants: An ancillary study of a 2 × 2 factorial randomized clinical trial involving 25 119 women and men aged 50 years or older without prior cardiovascular disease, cancer, or AF. Participants were recruited directly by mail between November 2011 and March 2014 from all 50 US states and were followed up until December 31, 2017. Interventions: Participants were randomized to receive EPA-DHA (460 mg/d of EPA and 380 mg/d of DHA) and vitamin D3 (2000 IU/d) (n = 6272 analyzed); EPA-DHA and placebo (n = 6270 analyzed); vitamin D3 and placebo (n = 6281 analyzed); or 2 placebos (n = 6296 analyzed). Main Outcomes and Measures: The primary outcome was incident AF confirmed by medical record review. Results: Among the 25 119 participants who were randomized and included in the analysis (mean age, 66.7 years; 50.8% women), 24 127 (96.1%) completed the trial. Over a median 5.3 years of treatment and follow-up, the primary end point of incident AF occurred in 900 participants (3.6% of study population). For the EPA-DHA vs placebo comparison, incident AF events occurred in 469 (3.7%) vs 431 (3.4%) participants, respectively (hazard ratio, 1.09; 95% CI, 0.96-1.24; P = .19). For the vitamin D3 vs placebo comparison, incident AF events occurred in 469 (3.7%) vs 431 (3.4%) participants, respectively (hazard ratio, 1.09; 95% CI, 0.96-1.25; P = .19). There was no evidence for interaction between the 2 study agents (P = .39). Conclusions and Relevance: Among adults aged 50 years or older, treatment with EPA-DHA or vitamin D3, compared with placebo, resulted in no significant difference in the risk of incident AF over a median follow-up of more than 5 years. The findings do not support the use of either agent for the primary prevention of incident AF. Trial Registration: ClinicalTrials.gov Identifiers: NCT02178410; NCT01169259.
Authors: David S Siscovick; Thomas A Barringer; Amanda M Fretts; Jason H Y Wu; Alice H Lichtenstein; Rebecca B Costello; Penny M Kris-Etherton; Terry A Jacobson; Mary B Engler; Heather M Alger; Lawrence J Appel; Dariush Mozaffarian Journal: Circulation Date: 2017-03-13 Impact factor: 29.690
Authors: Aaron L Farquharson; Robert G Metcalf; Prashanthan Sanders; Robert Stuklis; James R M Edwards; Robert A Gibson; Leslie G Cleland; Thomas R Sullivan; Michael J James; Glenn D Young Journal: Am J Cardiol Date: 2011-07-15 Impact factor: 2.778
Authors: Saurabh Kumar; Fiona Sutherland; Joseph B Morton; Geoffrey Lee; John Morgan; James Wong; David E Eccleston; John Voukelatos; Manohar L Garg; Paul B Sparks Journal: Heart Rhythm Date: 2011-11-23 Impact factor: 6.343
Authors: Stephen J Nicholls; A Michael Lincoff; Michelle Garcia; Dianna Bash; Christie M Ballantyne; Philip J Barter; Michael H Davidson; John J P Kastelein; Wolfgang Koenig; Darren K McGuire; Dariush Mozaffarian; Paul M Ridker; Kausik K Ray; Brian G Katona; Anders Himmelmann; Larrye E Loss; Martin Rensfeldt; Torbjörn Lundström; Rahul Agrawal; Venu Menon; Kathy Wolski; Steven E Nissen Journal: JAMA Date: 2020-12-08 Impact factor: 56.272
Authors: Brian C Boursiquot; Joseph C Larson; Omaima A Shalash; Mara Z Vitolins; Elsayed Z Soliman; Marco V Perez Journal: Am Heart J Date: 2018-12-13 Impact factor: 4.749
Authors: Daniel E Jonas; Leila C Kahwati; Jonathan D Y Yun; Jennifer Cook Middleton; Manny Coker-Schwimmer; Gary N Asher Journal: JAMA Date: 2018-08-07 Impact factor: 56.272
Authors: Maria Barsan; Anca Monica Brata; Abdulrahman Ismaiel; Dinu Iuliu Dumitrascu; Andrei-Vlad Badulescu; Traian Adrian Duse; Stefana Dascalescu; Stefan Lucian Popa; Simona Grad; Lucian Muresan; Carmen Maria Maerescu; Gabriel Cismaru; Vlad Dumitru Brata Journal: Biomedicines Date: 2022-05-26
Authors: Nan Zhang; Yueying Wang; Ziliang Chen; Daiqi Liu; Gary Tse; Panagiotis Korantzopoulos; Konstantinos P Letsas; Christos A Goudis; Gregory Y H Lip; Guangping Li; Zhiwei Zhang; Tong Liu Journal: Front Nutr Date: 2022-06-17
Authors: Baris Gencer; Luc Djousse; Omar T Al-Ramady; Nancy R Cook; JoAnn E Manson; Christine M Albert Journal: Circulation Date: 2021-10-06 Impact factor: 39.918
Authors: Amelie H Ohlrogge; Jan Brederecke; Francisco M Ojeda; Simon Pecha; Christin S Börschel; Lenard Conradi; Vanessa Rimkus; Stefan Blankenberg; Tanja Zeller; Renate B Schnabel Journal: Front Nutr Date: 2022-05-10
Authors: Katarina Andelova; Barbara Szeiffova Bacova; Matus Sykora; Peter Hlivak; Miroslav Barancik; Narcis Tribulova Journal: Int J Mol Sci Date: 2022-01-26 Impact factor: 5.923
Authors: Emelia J Benjamin; Sana M Al-Khatib; Patrice Desvigne-Nickens; Alvaro Alonso; Luc Djoussé; Daniel E Forman; Anne M Gillis; Jeroen M L Hendriks; Mellanie True Hills; Paulus Kirchhof; Mark S Link; Gregory M Marcus; Reena Mehra; Katherine T Murray; Ratika Parkash; Ileana L Piña; Susan Redline; Michiel Rienstra; Prashanthan Sanders; Virend K Somers; David R Van Wagoner; Paul J Wang; Lawton S Cooper; Alan S Go Journal: J Am Heart Assoc Date: 2021-08-05 Impact factor: 6.106